Gastric Counter-regulation Of Hypoglycaemia: Studies In Health And Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$357,193.00
Summary
Insulin injections are often needed to treat diabetes, but they can cause low blood sugar levels (hypoglycaemia), which are usually distressing, and sometimes fatal. The stomach is important in regulating blood sugar; in response to hypoglycaemia, it empties food much more rapidly, allowing carbohydrate to be absorbed faster to normalise blood sugar levels. The proposed studies will explore this important area, in order to develop better ways of preventing and treating hypoglycaemia.
Beta Cell Mass In Type 1 Diabetes Mellitus And Islet Transplantation
Funder
National Health and Medical Research Council
Funding Amount
$3,070,136.00
Summary
This research program will examine the cellular and molecular mechanisms underlying the loss of Beta cell mass and function: During the pathogenesis of Type 1 Diabetes Mellitus (T1D); and Following islet transplantation. Though these processes have traditionally been considered to be purely immune-mediated, it is now clear that the response of the beta cell is critical to the final outcome of the auto-immune process and response to therapeutic interventions. Thus the complex interactions between ....This research program will examine the cellular and molecular mechanisms underlying the loss of Beta cell mass and function: During the pathogenesis of Type 1 Diabetes Mellitus (T1D); and Following islet transplantation. Though these processes have traditionally been considered to be purely immune-mediated, it is now clear that the response of the beta cell is critical to the final outcome of the auto-immune process and response to therapeutic interventions. Thus the complex interactions between the cellular and soluble constituents of the immune system, plus the effects of a deregulated metabolic milieu, are integrated at the beta cell. This in turn activates a series of complex transcriptional programs in the beta cell that together determine the beta cells ultimate functional status and survival. We will use knowledge gained from studying these processes to drive the development of novel therapeutic targets and strategies to improve the success of immune-based and transplantation-based therapies.Read moreRead less
Intervening In The Natural History Of Type 1 Diabetes: An Integrated Approach
Funder
National Health and Medical Research Council
Funding Amount
$9,466,000.00
Summary
This Program brings together four of Australia’s top type 1 diabetes clinical and lab-based research teams. The program has three intersecting themes. The first theme, pathogenesis, focuses on early life and understanding why type 1 diabetes develops. The second theme, prevention, seeks to identifying new drugs to stop the disease from occurring. The third theme, treatment, aims to improve therapies to replace the cells that are destroyed during the disease process.
Transforming Mealtime Insulin Dosing Using An Innovative New Bolusing Calculator To Optimise Glycaemic Control In Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$318,768.00
Summary
People with type 1 diabetes require life-long insulin injections to maintain their blood glucose levels in the optimal range. Mealtime dose estimations based solely on carbohydrate have limited efficacy as they fail to take fat and protein into account. The aim of this project is to develop an evidence-based insulin bolusing calculator integrated into a smartphone app to enhance blood glucose control and reduce the daily burden of disease and the risk of life-threatening complications.
Free-Living Closed-Loop Insulin Delivery For Patients With Type 1 Diabetes: A Long-term Multi-centre Randomized Controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$1,041,986.00
Summary
Closed loop technology for automating the delivery of insulin to patients with Type 1 diabetes has the potential to improve the lives of many with the disease. Though early prototypes are currently under evaluation in small studies, no studies have yet to date applied the technology in a large scale randomised trial. We propose to undertake such a study in order to demonstrate the utility of this technology and facilitate its eventual routine and widespread use in the community in the future.
Type 1 Diabetes And The Metabolic Syndrome: Defining This Modern-day Phenotype, And Exploring The Effects Of Exercise On Glycaemic Control And Both Traditional And Novel Diabetes Complications
Funder
National Health and Medical Research Council
Funding Amount
$122,714.00
Summary
This research aims to define trends in the prevalence of, and complications associated with, metabolic syndrome in adults with type 1 diabetes, using the Australian National Diabetes Information Audit and Benchmarking Initiative (ANDIAB). Subsequently, a randomised controlled trial will examine the effect of exercise on glycaemic control and diabetes complications risk profiles in this group. These studies will thus address disease profiles and a potential beneficial clinical intervention.
Understanding The Early-life Pathways For Adult Type 2 Diabetes Using Existing Data From Seven Cohorts Of The International Childhood Cardiovascular Cohort (i3C) Consortium
Funder
National Health and Medical Research Council
Funding Amount
$336,419.00
Summary
This project will allow us to determine the role that child factors play in the development of diabetes. We will do this using information that has been collected from individuals at several ages extending from childhood to adulthood, somewhat like the “Up” TV series. The project’s findings could lead to improvements in the way we identify people who are at risk of having adult diabetes. By doing so, we could begin programs to stop the young from being struck down by this debilitating disease.
Targeting RCAN1 To Treat Type 2 Diabetes And Obesity
Funder
National Health and Medical Research Council
Funding Amount
$814,468.00
Summary
Obesity and impaired insulin secretion are significant contributors to Type 2 diabetes. In this project we demonstrate that a protein called RCAN1 contributes to both fat mass and insulin secretion and that this contribution is exacerbated in obesity and in Type 2 diabetes. We will identify how RCAN1 controls these major metabolic pathways with outcomes including the development of new therapeutics for obesity and Type 2 diabetes.
Closed-loop Insulin Delivery Compared With Islet Cell Transplantation For Adults With Type 1 Diabetes And Impaired Awareness Of Hypoglycaemia
Funder
National Health and Medical Research Council
Funding Amount
$92,745.00
Summary
Hypoglycaemia in adults with type 1 diabetes is common. Evaluation of therapies – the ‘artificial pancreas’ and islet cell transplantation - is warranted in a cohort with repeated episodes of hypoglycaemia. This proposal will assess whether the ‘artificial pancreas’ and islet cell transplantation, compared with usual insulin therapy, will reduce hypoglycaemia and improve other clinical outcomes over 6 months. This has potential to expand therapies used in current clinical practice.
Repurposing JAK Inhibitors To Treat Type 1 Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$947,874.00
Summary
Type 1 diabetes occurs when the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. Beta cells have to respond to molecules called cytokines for T cells to be able to kill them. We have identified a drug, called a JAK inhibitor, which will block the effects of cytokines on beta cells and cells of the immune system. The goal of this work is perform pre-clinical assessment of this drug, and test whether it has effects on type 1 diabetes in people.